OrthoPediatrics Corp. (NASDAQ:KIDS) Stock Now Rated “Moderate Buy” by Sell-Side Analysts

Shares of OrthoPediatrics Corp. (NASDAQ:KIDS) have been assigned an average recommendation of “Moderate Buy” from the nine brokerages that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $30.75.

Several equities analysts recently commented on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $35.00 price objective on shares of OrthoPediatrics in a research report on Wednesday, October 28th. Canaccord Genuity Group boosted their target price on shares of OrthoPediatrics from $28.00 to $30.00 and gave the stock a “buy” rating in a research report on Wednesday, October 28th. BTIG Research lifted their price objective on shares of OrthoPediatrics from $29.00 to $30.00 and gave the stock a “buy” rating in a research note on Wednesday, October 28th. Lake Street Capital boosted their price objective on shares of OrthoPediatrics from $34.00 to $38.00 and gave the company a “buy” rating in a report on Wednesday, October 28th. Finally, TD Cowen upped their target price on OrthoPediatrics from $23.00 to $28.00 and gave the company a “buy” rating in a research report on Wednesday, October 28th.

Insiders Place Their Bets

In related news, Director David R. Pelizzon sold 302,369 shares of OrthoPediatrics stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $21.01, for a total transaction of $6,352,772.69. Following the completion of the sale, the director owned 6,201,764 shares of the company’s stock, valued at $130,299,061.64. The trade was a 4.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, major shareholder Jennifer N. Pritzker sold 302,369 shares of the company’s stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $21.01, for a total value of $6,352,772.69. Following the completion of the sale, the insider owned 6,201,764 shares in the company, valued at approximately $130,299,061.64. This represents a 4.65% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 2,100,000 shares of company stock valued at $46,747,931. 32.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On OrthoPediatrics

Hedge funds have recently added to or reduced their stakes in the business. Riverbridge Partners LLC raised its stake in shares of OrthoPediatrics by 108.9% during the 3rd quarter. Riverbridge Partners LLC now owns 324,447 shares of the company’s stock valued at $7,225,000 after buying an additional 169,132 shares during the last quarter. AIGH Capital Management LLC boosted its stake in shares of OrthoPediatrics by 334.4% in the third quarter. AIGH Capital Management LLC now owns 1,171,765 shares of the company’s stock worth $26,095,000 after buying an additional 902,000 shares during the last quarter. Conestoga Capital Advisors LLC grew its holdings in OrthoPediatrics by 16.2% during the third quarter. Conestoga Capital Advisors LLC now owns 74,975 shares of the company’s stock worth $1,670,000 after acquiring an additional 10,440 shares during the period. Ellsworth Advisors LLC acquired a new position in OrthoPediatrics in the third quarter valued at approximately $900,000. Finally, GAMMA Investing LLC lifted its holdings in OrthoPediatrics by 70.3% in the third quarter. GAMMA Investing LLC now owns 1,165 shares of the company’s stock valued at $26,000 after acquiring an additional 481 shares during the period. 69.05% of the stock is owned by hedge funds and other institutional investors.

OrthoPediatrics Price Performance

OrthoPediatrics stock opened at $31.76 on Monday. OrthoPediatrics has a 1-year low of $14.42 and a 1-year high of $34.53. The business has a fifty day moving average price of $24.06 and a 200-day moving average price of $19.92. The company has a debt-to-equity ratio of 0.29, a current ratio of 4.55 and a quick ratio of 2.00. The stock has a market capitalization of $829.25 million, a price-to-earnings ratio of -22.21 and a beta of 0.90.

OrthoPediatrics (NASDAQ:KIDS) last announced its earnings results on Tuesday, October 27th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.02). OrthoPediatrics had a negative net margin of 12.83% and a negative return on equity of 8.10%. The business had revenue of $72.66 million for the quarter, compared to analyst estimates of $68.50 million. Equities research analysts forecast that OrthoPediatrics will post -1.09 EPS for the current fiscal year.

About OrthoPediatrics

OrthoPediatrics Corp. is a medical device company focused exclusively on developing and commercializing orthopedic products for children. The company designs implants, instruments and related technologies intended to address the distinct anatomical and clinical needs of pediatric patients, including those with congenital conditions, traumatic injuries and musculoskeletal disorders.

Its product portfolio covers pediatric trauma and deformity correction, scoliosis, limb reconstruction, sports medicine and other specialized orthopedic procedures.